Most Clicked StoriesMore >


MedImmune to form spinout with Abpro for bispecific antibody development

BIO SmartBrief | Nov 30, 2016

MedImmune and Abpro agreed to form a spinout that will develop a bispecific antibody that targets angiopoietin-2 and vascular endothelial growth factor for potential use in several therapeutic areas. The spinout will be named AbMed and will operate as a subsidiary of Abpro. Genetic Engineering & Biotechnology News (11/29)


AstraZeneca signs collaboration deal with Bicycle for up to $1B-plus

BIO SmartBrief | Dec 02, 2016

FDA fast-tracks Oragenics' oral mucositis treatment

BIO SmartBrief | Nov 28, 2016

FDA approves clinical trials of Alzheimer's/schizophrenia drug

BIO SmartBrief | Nov 29, 2016

Navidea to sell Lymphoseek to Cardinal for $80M-plus

BIO SmartBrief | Nov 28, 2016

Caltech spinoff raises $19.15M for gut-CNS therapies

BIO SmartBrief | Dec 02, 2016

21st Century Cures Act clears House

BIO SmartBrief | Dec 01, 2016

Heptares agrees to purchase G7 for $11.8M

BIO SmartBrief | Dec 01, 2016

Ariad's treatment for rare leukemias receives FDA approval

BIO SmartBrief | Dec 01, 2016

Merck's Keytruda given FDA priority review for lung cancer

BIO SmartBrief | Nov 29, 2016


Find BIO SmartBrief Issues by Date:



BIO News More >


Save $200 on the BIO CEO & Investor Conference if you register by Dec. 15!

BIO SmartBrief | Dec 02, 2016

Registration is open for the 2017 BIO Asia International Conference

BIO SmartBrief | Dec 02, 2016

Nikon

BIO SmartBrief | Dec 01, 2016

BIO Asia International Conference

BIO SmartBrief | Dec 01, 2016

Unifirst -- Latest version

BIO SmartBrief | Nov 30, 2016




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more